Review: Improving symptom control in early Parkinson’s disease

by Stuart H. Isaacson, Robert A. Hauser
Published 2009-11-01

Potential utility of amantadine DR/ER in persons with Parkinson’s disease meeting 5-2-1 criteria for device aided therapy

by Robert A. Hauser, Santosh Goud, Andrea E. Formella
Published 2022-01-01

A2A Receptor Antagonism and Dyskinesia in Parkinson’s Disease

by Micaela Morelli, Fabio Blandini, Nicola Simola, Robert A. Hauser
Published 2012-01-01

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease

by Robert A. Hauser, Judy Lytle, Andrea E. Formella, Caroline M. Tanner
Published 2022-03-01

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

by Stuart H. Isaacson, Robert A. Hauser, Rajesh Pahwa, David Gray, Sridhar Duvvuri
Published 2023-01-01

Sleep disorders in Parkinson’s disease

by Israt Jahan, Robert A Hauser, Kelly L Sullivan, Amber Miller, et al.
Published 2009-10-01

Higher neuron densities in the cerebral cortex and larger cerebellums may limit dive times of delphinids compared to deep-diving toothed whales.

by Sam H Ridgway, Robert H Brownson, Kaitlin R Van Alstyne, Robert A Hauser
Published 2019-01-01

Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice

by Khashayar Dashtipour, Fiona Gupta, Robert A. Hauser, Cherian A. Karunapuzha, John C. Morgan
Published 2021-01-01

Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease

by Robert A. Hauser, Ryan R. Walsh, Rajesh Pahwa, Dustin Chernick, Andrea E. Formella
Published 2021-03-01

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey

by Robert A. Hauser, Ghazal Banisadr, Kara Vuong, David Freilich, Stanley Fisher, Richard D’Souza
Published 2021-01-01

Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies

by Alberto Esquenazi, Mauricio R. Delgado, Robert A. Hauser, Philippe Picaut, Keith Foster, Andreas Lysandropoulos, Jean-Michel Gracies
Published 2020-09-01

Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search

by Gareth Morinan, Robert A. Hauser, Anette Schrag, Jingxuan Tang, Jonathan O’Keeffe, null MDS-NMS Scale Development Study Group
Published 2022-01-01

Minimal Clinically Important Difference in Parkinson’s Disease as Assessed in Pivotal Trials of Pramipexole Extended Release

by Robert A. Hauser, Mark Forrest Gordon, Yoshikuni Mizuno, Werner Poewe, Paolo Barone, Anthony H. Schapira, Olivier Rascol, Catherine Debieuvre, Mandy Fräßdorf
Published 2014-01-01

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia

by Rajesh Pahwa, Susan Fox, Robert A. Hauser, Stuart Isaacson, Judy Lytle, Reed Johnson, Lily Llorens, Andrea E. Formella, Caroline M. Tanner
Published 2022-10-01

Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a random...

by Atul T Patel, Mark F Lew, Khashayar Dashtipour, Stuart Isaacson, Robert A Hauser, William Ondo, Pascal Maisonobe, Stefan Wietek, Bruce Rubin, Allison Brashear
Published 2021-01-01

Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results f...

by Atul T Patel, Mark F Lew, Khashayar Dashtipour, Stuart Isaacson, Robert A Hauser, William Ondo, Pascal Maisonobe, Stefan Wietek, Bruce Rubin, Allison Brashear
Published 2021-01-01

AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

by Mark F. Lew, Robert A. Hauser, Stuart H. Isaacson, Daniel Truong, Atul T. Patel, Allison Brashear, William Ondo, Pascal Maisonobe, Khashayar Dashtipour, Laxman Bahroo, Stefan Wietek
Published 2021-01-01

Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase...

by Cynthia Comella, Robert A. Hauser, Stuart H. Isaacson, Daniel Truong, Odinachi Oguh, Jennifer Hui, Eric S. Molho, Matthew Brodsky, Erin Furr-Stimming, Georg Comes, Michael A. Hast, David Charles
Published 2022-01-01

Article Commentary: Infectious Issues in Human Fetal Neural Transplantation

by Douglas A. Holt, G. Michael Nauert, Agneta I. Othberg, Timothy S. Randall, Alison E. Willing, Ray H. Widen, Robert A. Hauser, Paul R. Sanberg, C. Warren Olanow, Thomas B. Freeman
Published 1997-11-01

Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study

by Robert A. Hauser, Hadas Barkay, Hubert H. Fernandez, Stewart A. Factor, Joohi Jimenez-Shahed, Nicholas Gross, Leslie Marinelli, Amanda Wilhelm, Jessica Alexander, Mark Forrest Gordon, Juha-Matti Savola, Karen E. Anderson
Published 2022-02-01